Skip to main content
Erschienen in: Supportive Care in Cancer 1/2024

01.01.2024 | Introduction

MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update

verfasst von: J. Herrstedt, R. Clark-Snow, C. H. Ruhlmann, K. Jordan, F. Scotté

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

The Multinational Association of Supportive Care in Cancer (MASCC) had their first antiemetic guideline consensus conference in Perugia in 1997 [1, 2] and updated the guidelines in 2004 [3, 4]. The European Society for Medical Oncology (ESMO) published their first antiemetic guideline in 2001 [5] with annual updates in subsequent years. In 2009 the two societies joined forces and published mutual antiemetic guidelines based on consensus meetings in 2009 (Perugia) and 2015 (Copenhagen). An Expert Committee was appointed by the two societies with 10 working groups identified to update specific antiemetic recommendations. The guidelines were published in Annals of Oncology in 2010 [6] and 2016 [7] as one review paper of all recommendations and in 10 papers in Supportive Care in Cancer in 2011 and 2017 as extended reviews of the recommendations from each of the 10 working groups. …
Literatur
1.
Zurück zum Zitat Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference. Ann Oncol 9:811–819 Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference. Ann Oncol 9:811–819
3.
Zurück zum Zitat The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28. https://doi.org/10.1093/annonc/mdj078 The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28. https://​doi.​org/​10.​1093/​annonc/​mdj078
5.
Zurück zum Zitat J Herrstedt on behalf of the ESMO Guidelines Task Force (2001) ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 12:1059–1060 J Herrstedt on behalf of the ESMO Guidelines Task Force (2001) ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 12:1059–1060
6.
Zurück zum Zitat Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-243CrossRefPubMed Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-243CrossRefPubMed
7.
Zurück zum Zitat Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefPubMed Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefPubMed
9.
Zurück zum Zitat Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71CrossRefPubMedPubMedCentral Page MJ, McKenzie JE, Bossuyt PM et al (2021)  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Dykewicz CA (2001) Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33(2):139–144CrossRefPubMed Dykewicz CA (2001) Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33(2):139–144CrossRefPubMed
11.
Zurück zum Zitat Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, lihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scotté F on behalf of the participants of the MASCC/ESMO Consensus Conference 2022 (2023) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 2023. in press Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, lihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scotté  F on behalf of the participants of the MASCC/ESMO Consensus Conference 2022 (2023) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 2023. in press
Metadaten
Titel
MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update
verfasst von
J. Herrstedt
R. Clark-Snow
C. H. Ruhlmann
K. Jordan
F. Scotté
Publikationsdatum
01.01.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2024
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-023-08219-y

Weitere Artikel der Ausgabe 1/2024

Supportive Care in Cancer 1/2024 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.